Drugs / IL-12 gene therapy
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04095689 | May 2021 → Jun 2024 | triple-negative breast carcinoma | The Methodist Hospital Research Institute | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IL-12 gene therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04095689 ↗ |
| Known as | ADV/IL-12 | “adenoviral-mediated interleukin-12 (ADV/IL-12) gene therapy” NCT04095689 ↗ |
| Action | Activate | “IL-12 stimulates T cells” NCT04095689 ↗ |